Anti angiotensin II vaccine
Immune therapy for the treatment of hypertension receiving ever greater attention
The possibility of using immune technologies to develop more targeted drugs for the treatment of hypertension has been receiving ever greater attention .
It is well known that angiotension II and angiotension II receptors play a key role in the development of hypertension. Thus, angiotension II became a target for immunotherapeutic approaches to treat hypertension, which is often referred to as “angiotensin II vaccine”, “anti angiotensin II vaccine”, or “hypertension vaccine”.
In fact, an immune therapy, respectively an active immunization, which would induce antibodies against angiotensin II or angiotensin II receptors, could improve medication adherence owing to lower administration frequency based on prolonged therapeutic effects.
CRS is a pioneer in the clinical development of a hypertension vaccine
CRS is very proud to be a pioneer in performing a clinical trial with a new innovative drug or rather a vaccine, precisely an “anti angiotensin II vaccine,” developed for the treatment of patients with mild to moderate essential hypertension.
All in all, an immune therapy, as outlined above, would constitute a major step forward in the treatment of patients with essential hypertension.
 Azegam T, Itoh H: Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension. Int J Hypertens. 2019; 2019:9218531. https://doi.org/10.1155/2019/9218531.
 Carretero OA, Oparil S: Essential Hypertension – Part I: Definition and Etiology. Circulation. 2000;101:329–335. https://doi.org/10.1161/01.CIR.101.3.329.
 Watanabe R, Suzuki J, Wakayama K et al.: A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Sci Rep 7, 43920 (2017). https://doi.org/10.1038/srep43920.